Akashi Takuya, Furuya Yuzo, Ohta Shoichiro, Fuse Hideki
Department of Urology, Toyama Medical and Pharmaceutical University Faculty of Medicine, Sugitani, Toyama, Japan.
Urology. 2003 Dec;62(6):1078-82. doi: 10.1016/s0090-4295(03)00768-4.
To assess immunohistochemically the pattern of tissue factor (TF) expression in patients with metastatic prostate cancer, because TF is aberrantly expressed in human cancer. TF is the primary initiator of the coagulation cascade.
Seventy-three patients with untreated metastatic prostate cancer who received hormonal therapy were included in the present study. Biopsy specimens were stained with anti-human TF antibody. We evaluated the histologic grade, extent of bony metastasis, clinical response to hormonal therapy, and patient prognosis.
TF was detected in 75.3% of the tumors of the patients with metastatic prostate cancer. TF expression showed no association with histologic grade, extent of bony metastasis, or clinical response to hormonal therapy. Patients with TF-positive tumors had a poorer cause-specific survival than those with TF-negative tumors. Multivariate analysis showed that TF expression, clinical response to hormonal therapy, and extent of bony metastasis were significant prognostic factors.
The TF content measured using immunohistochemical staining was a useful prognostic factor for patients with metastatic prostate cancer treated with androgen withdrawal therapy.
鉴于组织因子（TF）在人类癌症中存在异常表达，且TF是凝血级联反应的主要启动因子，故采用免疫组织化学方法评估转移性前列腺癌患者的TF表达模式。
本研究纳入73例接受激素治疗的未经治疗的转移性前列腺癌患者。活检标本用抗人TF抗体染色。我们评估了组织学分级、骨转移程度、对激素治疗的临床反应以及患者预后。
在转移性前列腺癌患者的75.3%的肿瘤中检测到TF。TF表达与组织学分级、骨转移程度或对激素治疗的临床反应无关。TF阳性肿瘤患者的病因特异性生存率低于TF阴性肿瘤患者。多变量分析显示，TF表达、对激素治疗的临床反应和骨转移程度是重要的预后因素。
使用免疫组织化学染色测量的TF含量是接受雄激素剥夺治疗的转移性前列腺癌患者的有用预后因素。
